TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11192308
Drug: Leucocyte‐depletion filters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucocyte‐depletion filters added to the CPB circuit (treatment group)
Study: 4028627
Drug: Acifran 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acifran 100 mg t.i.d.
Study: 4028627
Drug: Acifran 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acifran 300 mg t.i.d.
Study: 30476108
Drug: Isavuconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isavuconazole (200 mg) administered three times daily for 2 days, then once daily.
Study: 27312961
Drug: Home modifications
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home modifications (e.g., handrails, grab rails, outside lighting, edging for outside steps, slip-resistant surfacing)
Study: 27097430
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine hemorrhoids lotion for fumigation
Study: 27097430
Drug: 1 000
Normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 000 mL 1: 5 000 potassium permanganate solution for sitz bath
Study: 23181832
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg folic acid
Study: 23181832
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg folic acid
Study: 23380913
Drug: Combined folic
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined folic acid groups (0.4 mg and 4 mg)
Study: 14652439
Drug: Nimodipine 30
Normalized name: nimodipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 30 mg Q6H
Study: 10224639
Drug: Self-management therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management therapy with choice of target (behavioral or cognitive)
Study: 10224639
Drug: Self-management therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management therapy without choice of target
Study: 10224639
Drug: Self-management therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management therapy with choice of target
Study: 9085491
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg dose of ritanserin
Study: 20884122
Drug: Praziquantel 40
Normalized name: PRAZIQUANTEL 40 mg in 1 mL ORAL SOLUTION [A Vial]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel 40 mg/kg
Study: 6401550
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with niridazole 25 mg/kg and metrifonate 10 mg/kg
Study: 6401550
Drug: Metrifonate 10
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate 10 mg/kg
Study: 26856191
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline (HS) inhalation
Study: 26856191
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (IS) inhalation
Study: 22530354
Drug: Etanercept (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (50 mg/week) + Teriparatide (20 mg)
Study: 18502991
Drug: Timolol-dorzolamide fixed
Normalized name: dorzolamide / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol-dorzolamide fixed combination (TDFC)
Study: 18502991
Drug: Timolol-dorzolamide fixed
Normalized name: dorzolamide / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol-dorzolamide fixed combination (TDFC) and Latanoprost 0.005%
Study: 10215732
Drug: LAC (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAC (lansoprazole 30 mg b.d., amoxycillin 500 mg b.d., clarithromycin 400 mg b.d. for 7 days)
Study: 10215732
Drug: LACP (LAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: LACP (LAC regimen plus polaprezinc 150 mg b.d. for 7 days)
Study: 7869193
Drug: Luteinizing hormone-releasing
Normalized name: (6-D-Tryptophan)luteinizing hormone-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteinizing hormone-releasing hormone (LH‐RH) stimulation tests in children with NF‐1 and OPTs
Study: 7869193
Drug: Luteinizing hormone-releasing
Normalized name: (6-D-Tryptophan)luteinizing hormone-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteinizing hormone-releasing hormone (LH‐RH) stimulation tests in children without OPTs (control group)
Study: 1694235
Drug: Alternating chemotherapy
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating chemotherapy regimens (MOPP/ABVD; CAD plus MOPP plus ABV) combined with intermediate-dose radiation therapy (RT)
Study: 621612
Drug: Chlorambucil stable
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorambucil stable dose (0.2 mg/kg/day) for 56 to 60 days
Study: 621612
Drug: Chlorambucil increasing
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorambucil increasing doses (0.2 to 0.63 mg/kg/day) for 42 to 77 days
Study: 621612
Drug: Prednisone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (60 mg/m2 on alternate days)
Study: 30422390
Drug: Praliciguat (15/30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praliciguat (15/30 mg, 20/40 mg, 30/40 mg, and weight-based)
Study: 28695804
Drug: Calcium 600
Normalized name: Calcium 600
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium 600 mg/d + VitD3 800 U/d (group C)
Study: 28695804
Drug: Calcium 600
Normalized name: Calcium 600
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium 600 mg/d + 25 hydroxyl vitamin D (25OHD) 0.25 μg/d (group D)
Study: 26679652
Drug: 5.0 g
Normalized name: IODINE 5.0 g in 1 L TOPICAL SOLUTION [FS-104]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 g sucrose gel
Study: 26679652
Drug: 5.0 g
Normalized name: IODINE 5.0 g in 1 L TOPICAL SOLUTION [FS-104]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 g metronidazole gel
Study: 19091346
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg finasteride daily for at least 30 days before surgery
Study: 17407636
Drug: Varenicline 1
Normalized name: varenicline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 1 mg twice daily (BID)
Study: 18084743
Drug: Varenicline 1
Normalized name: varenicline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 1 mg BID
Study: 11172832
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg three times daily for 7 weeks)
Study: 9645591
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose inhaled fluticasone propionate (250 microg b.d.)
Study: 8942333
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg kg‐1 during desflurane anaesthesia
Study: 8942333
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg kg‐1 during isoflurane anaesthesia
Study: 30784955
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (24 IU twice daily)
Study: 18378374
Drug: Dopaminergic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopaminergic medication (on)
Study: 18378374
Drug: Dopaminergic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopaminergic medication (off)
Study: 16706961
Drug: Low-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity warfarin (target INR 1.5-2.0)
Study: 12905053
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg Solu‐Medrol intravenously and 160 mg Depo‐Medrol intramuscularly, plus 80 mg Depo‐Medrol on the dural sac
Study: 10977010
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium supplementation after 3 months of metformin therapy
Study: 7488478
Drug: Wound infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wound infiltration with ketorolac 30 mg in saline
Study: 7488478
Drug: Wound infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wound infiltration with ketorolac 30 mg with 0.25% bupivacaine
Study: 7488478
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (ketorolac 60 mg i.m.)
Study: 6124470
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg bromazepam
Study: 6118830
Drug: 3.0 mg
Normalized name: TOBRAMYCIN 3.0 mg in 1 mL OPHTHALMIC SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg bromazepam
Study: 26459358
Drug: FES treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FES treatment group (n = 16)
Study: 21496936
Drug: Group MVB:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group MVB: zinc (20 mg), magnesium (250 mg), vitamin C (200 mg), vitamin E (100 mg), vitamin B1 (10 mg), B2 (10 mg), B6 (10 mg), biotin (200 μg), B12 (10 μg), folic acid (1 mg)
Study: 21496936
Drug: Group MV:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group MV: zinc (20 mg), magnesium (250 mg), vitamin C (200 mg), vitamin E (100 mg)
Study: 17718106
Drug: Zileuton CR,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zileuton CR, 1,200 mg twice daily
Study: 17718106
Drug: Placebo CR,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo CR, twice daily
Study: 11440290
Drug: Topical 0.5%
Normalized name: phenol topical 0.5% topical spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.5% fluorouracil once daily for up to 28 days
Study: 11440290
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% fluorouracil twice daily for up to 28 days
Study: 9505769
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus of 5 ml of 0.375% bupivacaine hourly
Study: 9505769
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 5 ml of 0.375% bupivacaine hourly
Study: 7829766
Drug: Hydrocortisone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (20 mg, orally, twice daily)
Study: 1832761
Drug: rilmenidine 1
Normalized name: rilmenidine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rilmenidine 1 mg/day
Study: 2894164
Drug: rilmenidine 1
Normalized name: rilmenidine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rilmenidine 1 mg twice a day
Study: 29883974
Drug: saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline infusion (placebo)
Study: 27172830
Drug: Rotigotine (<8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine (<8 mg/24 h)
Study: 25393877
Drug: Pentoxifylline (PTX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (PTX), Ursodeoxycholic acid (UDCA), and low-dose low molecular weight heparin (LMWH) for 8 weeks
Study: 21084988
Drug: Cyanoacrylate injection
Normalized name: ethyl cyanoacrylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyanoacrylate injection (CI)
Study: 18306109
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g Hsp-G administered every morning for 12 weeks (n = 9)
Study: 18306109
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered every morning for 12 weeks (n = 10)
Study: 17186321
Drug: Moderate concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate concentration contrast medium (300 mg I/ml)
Study: 17186321
Drug: High concentration
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High concentration contrast medium (370 mg I/ml)
Study: 12707842
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural group therapy programme (16 group sessions of 90 min each)
Study: 12707842
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural group therapy programme
Study: 29562806
Drug: Calcitriol therapy
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol therapy
Study: 3885979
Drug: Intravenous timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous timolol (54 patients)
Study: 29402341
Drug: 19SP (finished
Approvals — FDA: no, EMA: no, PMDA: no
Description: 19SP (finished at pasture supplemented with 5 kg DM of concentrate per head daily for 100 days)
Study: 29402341
Drug: 19LP (finished
Approvals — FDA: no, EMA: no, PMDA: no
Description: 19LP (finished at pasture supplemented with 5 kg DM of concentrate per head daily for 150 days)
Study: 29402341
Drug: 24MO (finished
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24MO (finished indoors over the second winter on grass silage ad libitum plus 5 kg DM of concentrate per head daily)
Study: 29402341
Drug: 21SP (finished
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21SP (finished at pasture, supplemented with 5 kg DM of concentrate per head daily for 60 days)
Study: 29402341
Drug: 21LP (finished
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21LP (finished at pasture, supplemented with 5 kg DM of concentrate per head daily for 110 days)
Study: 22357140
Drug: Inotuzumab ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inotuzumab ozogamicin 1.8 mg/m² intravenously over 1 hour every 3-4 weeks (initially 1.3 mg/m² for first three adults and three children)
Study: 22357140
Drug: Inotuzumab ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inotuzumab ozogamicin (first course 1.3 mg/m²)
Study: 15848699
Drug: Daclizumab dosing
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclizumab dosing strategies
Study: 15041394
Drug: No antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibody induction
Study: 23161124
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care program
Study: 7648980
Drug: Aspirin 350
Normalized name: aspirin 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 350 mg/day for two weeks
Study: 7648980
Drug: Aspirin 1400
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 1400 mg/day for two weeks
Study: 2744905
Drug: Intracoronary nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary nicardipine (0.4 mg)
Study: 25898472
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) progesterone in oil 100 mg daily
Study: 25898472
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized progesterone followed by compounded vaginal progesterone 200 mg 3 times daily (OV)
Study: 23141881
Drug: THC/CBD oromucosal
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC/CBD oromucosal spray (n=39)
Study: 23141881
Drug: THC oromucosal
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC oromucosal spray (n=4)
Study: 18699801
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 200 microg twice daily for 14 days
Study: 2371597
Drug: Topical 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5-fluorouracil (5-FU)
Study: 8815753
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (methylprednisolone and cyclophosphamide)
Study: 8815753
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy vs Methylprednisolone
Study: 1519208
Drug: Gemfibrozil 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 1,200 mg/day
Study: 6395276
Drug: Cefonicid (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefonicid (1.0 g once daily intramuscularly or intravenously)
Study: 6395276
Drug: Cefazolin (0.5‐1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (0.5‐1.0 g three times a day intramuscularly or intravenously)
Study: 24766062
Drug: Secondary care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary care treatment
Study: 16769235
Drug: Paroxetine (PXT)
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paroxetine (PXT) 30 mg tid for two weeks
Study: 14740955
Drug: Formulations 1-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulations 1-15 (10^5-6 PFU/dose or 10^3.5-4.5 PFU/dose)
Study: 9467328
Drug: Combined phototherapy/low-intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined phototherapy/low-intensity laser therapy (CLILT) at 2.5 Hz
Study: 9467328
Drug: Combined phototherapy/low-intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined phototherapy/low-intensity laser therapy (CLILT) at 5 Hz
Study: 9467328
Drug: Combined phototherapy/low-intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined phototherapy/low-intensity laser therapy (CLILT) at 20 Hz
Study: 1593244
Drug: Active transdermal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active transdermal nicotine system
Study: 3914023
Drug: PGI2 infusion
Normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGI2 infusion (10 mg/kg.min for 24 hours)
Study: 30590701
Drug: AGO2 loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGO2 loading with G-rich sequences
Study: 24999670
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT)
Study: 19931154
Drug: Propofol (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (loading dose of 1 mg/kg over 15 minutes followed by maintenance of 1 to 3 mg/kg per hour)
Study: 19931154
Drug: Dexmedetomidine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (loading dose of 1 microg/kg over 10 minutes followed by maintenance of 0.2 to 2.5 microg/kg per hour)
Study: 19023429
Drug: 6% cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% cellulose sulfate vaginal gel
Study: 12792790
Drug: 5'‐DFUR (460
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5'‐DFUR (460 mg/m(2)/day) + PSK (3 g/day)
Study: 12792790
Drug: 5‐FU (115
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU (115 mg/m(2)/day) + PSK (3 g/day)
Study: 8781697
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of vaginal prostaglandin E2 as outpatient treatment
Study: 8781697
Drug: Expectant management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectant management with twice weekly surveillance tests
Study: 6729259
Drug: Choline theophyllinate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline theophyllinate, 600 mg orally
Study: 24999104
Drug: Common atropine
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common atropine (CA) gel
Study: 24999104
Drug: Modified atropine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified atropine (MA) gel
Study: 10442679
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme (ACE) inhibitor as first-line treatment
Study: 10442679
Drug: Diuretic added
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diuretic added to ACE inhibitor
Study: 11933550
Drug: Carvedilol (beta-blocker)
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol (beta-blocker)
Study: 10442679
Drug: ACE inhibitors,
Normalized name: ACE INHIBITORS, PLAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors, diuretics, beta-blockers (e.g. carvedilol), and digoxin
Study: 18324601
Drug: Combined programme
Normalized name: PUMP,LUTREPULSE PROGRAMMABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined programme (intensive psychosocial relapse-prevention + anxiety treatment with cognitive behavioural therapy and optional SSRI)
Study: 12957248
Drug: RT dose
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RT dose <75 Gy + STAD (Group A)
Study: 12957248
Drug: RT dose
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RT dose >=75 Gy alone (Group B)
Study: 10897156
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of lamotrigine (100 mg)
Study: 10897156
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of lamotrigine (100 mg)
Study: 1570385
Drug: Nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide administered during acquisition
Study: 3045295
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg orally)
Study: 3880523
Drug: Edrophonium (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium (10 mg i.v.)
Study: 3880523
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg orally) and Edrophonium (10 mg i.v.)
Study: 6111742
Drug: Analgesic drugs
Normalized name: ANALGESIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic drugs
Study: 29976193
Drug: Social and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social and Therapeutic Horticulture (STH) intervention with 6 monthly sessions led by horticulturists and a psychotherapist
Study: 20598993
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg pretreatment before PCI
Study: 18240191
Drug: Intensive exercise
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive exercise therapy (IET)
Study: 11245027
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with CP (cisplatin + cyclophosphamide) or CAP (CP + adriamycin) regimen